NANO4 GLOBAL LDA

Their core work

Nano4 Global is a Portuguese nanotechnology SME specializing in nano-based molecular diagnostics, with a specific focus on colorimetric methods for the rapid and affordable detection of bacteria and pathogens. Their core technology translates nanotechnology into practical diagnostic tools — the kind that can work outside a full laboratory setting, where speed and cost are critical. They successfully progressed through both phases of the EU SME Instrument, proving concept feasibility in 2017 and then receiving EUR 1.4M to develop a commercial-grade precision nanodiagnostics product between 2018 and 2021. Their value proposition is making precision nanodiagnostics fast enough and cheap enough for real-world deployment.

What they specialise in

How they've shifted over time

Nano4's H2020 trajectory follows a tight, linear development arc rather than a diversification story. In 2017 they validated the core concept of nano-based bacterial detection with a small feasibility grant (EUR 50,000 SME Phase 1), then in 2018 they moved directly into full product development with a EUR 1.4M SME Phase 2 award covering the same core technology. There is no detectable pivot in focus — the evolution is one of maturity and scale, not direction. This suggests an organisation that entered EU funding with a specific commercial goal and executed it in a disciplined, linear path toward market.

Nano4 completed their SME Phase 2 project in 2021, meaning they are likely in or approaching commercial deployment of their nanodiagnostics product — making them a potential technology licensing or supply partner rather than a research collaborator.

How they like to work

Nano4 operated as sole coordinator on both H2020 projects with no recorded consortium partners — which is entirely consistent with the SME Instrument format, designed for single-company innovation development. This means their EU funding history reflects commercial ambition rather than scientific networking. Anyone engaging them should expect a technology provider or spin-out relationship rather than a co-development consortium dynamic; they are builders of proprietary technology, not integrators of large research networks.

Nano4 has no recorded consortium partners across their entire H2020 portfolio, which reflects their exclusive use of the SME Instrument — a solo-applicant funding scheme. They have no documented international collaborative network from this data.

What sets them apart

Nano4 is one of a small number of Portuguese nanotechnology SMEs to have secured both SME Instrument Phase 1 and Phase 2 funding on the same technology — a competitive double validation that confirms both scientific credibility and commercial viability in the eyes of EU evaluators. Their specific niche (colorimetric, affordable, rapid bacterial detection) sits at a commercially valuable intersection: clinical diagnostics, food safety, and environmental testing all need exactly this kind of tool. For consortium builders in health, food, or environmental projects, they bring proprietary nano-detection IP that is closer to a product than a research prototype.

Highlights from their portfolio

• Nano4 (SME-2)
  The largest project at EUR 1,420,230 represents a full commercial development grant for colorimetric precision nanodiagnostics — one of the higher-value SME Instrument Phase 2 awards, signalling strong evaluator confidence in both the technology and the business case.
• Nano4 (SME-1)
  The 2017 feasibility study established the founding concept of nano-based early bacterial detection and directly seeded the Phase 2 award, demonstrating a disciplined and successful SME Instrument progression.